CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
40 hedge funds and large institutions have $39.2M invested in CTI BioPharma Corp. (DE) Common Stock in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 9 closing their positions.
87% more capital invested
Capital invested by funds: $21M → $39.2M (+$18.2M)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
7% less funds holding
Funds holding: 43 → 40 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$256K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$169K |
| 3 |
Renaissance Technologies
New York
|
+$85.3K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$40.7K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$14.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$197K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$134K |
| 3 |
JP Morgan Chase
New York
|
-$123K |
| 4 |
Squarepoint
New York
|
-$75K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$67K |
CTIC Hedge Fund Activity: Q4 2019 in Review
40 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2019, worth a combined $39.2M — up 87% from $21M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CTIC and 6 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was BlackRock, adding an estimated $256K. The largest seller was Millennium Management, cutting an estimated $197K.
- 40 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2019, down from 43 in Q3 2019.
- Funds reported $39.2M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2019, up 87% quarter-over-quarter.
- 6 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2019 and 9 closed out, a net change of -3 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2019 was BlackRock, an estimated $256K added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2019 was Millennium Management, an estimated $197K sold.
Based on aggregated 13F filings for Q4 2019.